STEVENSON, Md., March 07, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Obalon Therapeutics, Inc. (Nasdaq:OBLN) (“Obalon” or the “Company”) securities during the period between October 5, 2016 and January 23, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 16, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Obalon securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company recognized revenue in violation of Generally Accepted Accounting principles and that the Company lacked adequate internal controls over accounting and financial reporting.
According to the complaint, following Obalon’s January 23, 2018 a press release disclosing that “a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017” and that “Obalon’s Audit Committee will oversee an internal investigation of these allegations,” the value of Obalon shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Obalon securities purchased on or after October 5, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
OpenAI Restricts Astra AI Over Cyberattack Risks
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 



